196 related articles for article (PubMed ID: 19721436)
1. Rethinking therapeutic cancer vaccines.
Nat Rev Drug Discov; 2009 Sep; 8(9):685-6. PubMed ID: 19721436
[No Abstract] [Full Text] [Related]
2. Future of immunotherapy drug combinations and biomarkers.
Schmidt C
J Natl Cancer Inst; 2012 Mar; 104(6):434-9. PubMed ID: 22402694
[No Abstract] [Full Text] [Related]
3. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
Nelson B
Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
[No Abstract] [Full Text] [Related]
4. Cancer immunotherapy.
Bender E
Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244
[No Abstract] [Full Text] [Related]
5. Cancer immunotherapy.
White RL; Amin A
Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920
[TBL] [Abstract][Full Text] [Related]
6. Cancer vaccines: what do we need to measure in clinical trials?
Kudrin A
Hum Vaccin Immunother; 2014; 10(11):3236-40. PubMed ID: 25483508
[TBL] [Abstract][Full Text] [Related]
7. Vaccine immunotherapy for cancer.
Bridgewater J; Collins M
Mol Cell Biol Hum Dis Ser; 1995; 5():140-56. PubMed ID: 9532565
[No Abstract] [Full Text] [Related]
8. Cellular immunotherapy licensed for advanced prostate cancer.
Traynor K
Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
[No Abstract] [Full Text] [Related]
9. Therapeutic cancer vaccines: past, present, and future.
Guo C; Manjili MH; Subjeck JR; Sarkar D; Fisher PB; Wang XY
Adv Cancer Res; 2013; 119():421-75. PubMed ID: 23870514
[TBL] [Abstract][Full Text] [Related]
10. Consultation corner. Prostate cancer vaccine offers new direction.
Drake C
Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753
[No Abstract] [Full Text] [Related]
11. The dawn of vaccines for cancer prevention.
Finn OJ
Nat Rev Immunol; 2018 Mar; 18(3):183-194. PubMed ID: 29279613
[TBL] [Abstract][Full Text] [Related]
12. Cancer vaccines.
Nakamura Y
Clin Adv Hematol Oncol; 2011 Oct; 9(10):778-9. PubMed ID: 22252581
[No Abstract] [Full Text] [Related]
13. The Provenge decision.
DeVita VT
Nat Clin Pract Oncol; 2007 Jul; 4(7):381. PubMed ID: 17554239
[No Abstract] [Full Text] [Related]
14. Therapeutic cancer vaccines: From initial findings to prospects.
Song Q; Zhang CD; Wu XH
Immunol Lett; 2018 Apr; 196():11-21. PubMed ID: 29407608
[TBL] [Abstract][Full Text] [Related]
15. Personalized Cancer Vaccines Advance in the Clinic.
Schmidt C
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29095978
[No Abstract] [Full Text] [Related]
16. The fourth modality: immunotherapy for head and neck cancer hits pay dirt.
Bell RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jun; 121(6):575-7. PubMed ID: 27181440
[No Abstract] [Full Text] [Related]
17. Advances in strategies and methodologies in cancer immunotherapy.
Lam SS; Zhou F; Hode T; Nordquist RE; Alleruzzo L; Raker J; Chen WR
Discov Med; 2015 Apr; 19(105):293-301. PubMed ID: 25977192
[TBL] [Abstract][Full Text] [Related]
18. Clinical cancer vaccine trials.
Jäger E; Jäger D; Knuth A
Curr Opin Immunol; 2002 Apr; 14(2):178-82. PubMed ID: 11869889
[TBL] [Abstract][Full Text] [Related]
19. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
20. Cancer vaccines on the horizon.
Jones D
Nat Rev Drug Discov; 2007 May; 6(5):333-4. PubMed ID: 17539052
[No Abstract] [Full Text] [Related]
[Next] [New Search]
